Skip to main content

Table 2 Linear mixed model results of MCI and Dementia groups for plasma TG/HDL ratios and ApoA1 levels, and CSF ApoA1 levels

From: Metabolic syndrome biomarkers relate to rate of cognitive decline in MCI and dementia stages of Alzheimer’s disease

 

MCI group

Dementia group

Effect

Slope

(95% CI)

p-value

Slope

(95% CI)

p-value

MMSE

 CSF ApoA1

0.204

(0.030,0.377)

0.022

 − 0.683

(− 1.525,0.159)

0.11

 Plasma ApoA1

 − 0.498

(− 0.744, − 0.253)

< 0.001

 − 1.546

(− 3.080, − 0.012)

0.048

 TG/HDL ratio

 − 0.127

(− 0.251, − 0.004)

0.043

 − 0.299

(− 1.063, 0.466)

0.44

CDR-SB

 CSF ApoA1

 − 0.025

(− 0.148, 0.099)

0.69

0.112

(− 0.383, 0.607)

0.65

 Plasma ApoA1

0.141

(− 0.041, 0.324)

0.13

0.784

(− 0.118, 1.686)

0.088

 TG/HDL ratio

0.116

(0.024, 0.207)

0.013

0.472

(0.023, 0.921)

0.040

LM

 CSF ApoA1

 − 0.002

(− 0.144, 0.140)

0.97

0.203

(− 0.145, 0.550)

0.25

 Plasma ApoA1

 − 0.303

(− 0.502, − 0.103)

0.003

 − 0.424

(− 1.053, 0.204)

0.18

 TG/HDL ratio

0.009

(− 0.091,0.109)

0.87

0.141

(− 0.182, 0.464)

0.39

  1. MMSE, Mini-Mental Status Exam score; CDR-SB, Clinical Dementia Rating Scale–Sum of Boxes score; LM, logical memory delayed recall score. Positive slope notes faster progression CDR-SB; negative slope notes faster progression in MMSE and LM